Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocelullar carcinoma cells

Molecules and Cells

Volumn 21, Issue 1, 2006, Pages 104-111

  Cao, Limin ^a,c   Si, Jin ^b   Wang, Weiyu ^d   Zhao, Xiaorong ^a   Yuan, Xiaomei ^a   Zhu, Huifen ^a   Wu, Xiaolong ^c   Zhu, Jianzhong ^c   Shen, Guanxin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^c NANTONG UNIVERSITY   (China)

^d Tongji Hospital   (China)

Author keywords

Bystander effect; Cancer gene therapy; Ganciclovir; HIV 1 TAT; Intercellular translocation; Protein transduction; Thymidine kinase

Indexed keywords

GANCICLOVIR; HYBRID PROTEIN; THYMIDINE KINASE; TRANSACTIVATOR PROTEIN; PRODRUG;

ARTICLE; BYSTANDER EFFECT; CELL KILLING; CELL LINE; CELL STRAIN HEPG2; CYTOTOXICITY; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; WESTERN BLOTTING; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS; ESCHERICHIA COLI; GENE EXPRESSION; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; PROTEIN BINDING; SUICIDE TRANSGENE; TUMOR CELL LINE;

HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

BYSTANDER EFFECT; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; ESCHERICHIA COLI; GENE EXPRESSION; GENE PRODUCTS, TAT; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; PRODRUGS; PROTEIN BINDING; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE;

EID: 33645747836     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Akyurek, L. M., Nallamshetty, S., Aoki, K., San, H., Yang, Z. Y., et al. (2001) Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo. Mol. Ther. 3, 779-786.
2. Benedetti, S., Dimeco, F., Pollo B., Cirenei, N., Colombo, B. M., et al. (1997) limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum. Gene Ther. 8, 1345-1353.
3. Bilbao, R., Gerolami, R., Bralet, M. P., Qian, C., Tran, P.L., et al. (2000) Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther. 7, 657-662.
4. Bremner, K. H., Seymour, L. W., and Pouton, C. W. (2001) Harnessing nuclear localization pathways for transgene delivery. Curr. Opin. Mol. Ther. 3, 170-177.
5. Brunner, S., Sauer, T., Carotta, S., Cotton, M., Saltik, M., et al. (2000) Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther. 7, 401-407.
6. Chen, S. H., Kosai, K., Xu, B., Pham-Nguyen, K., Contant, C., et al. (1996) Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56, 3758-3762.
7. Danthinne, X., Aoki K., Kurachi, A. T., Nabel, G. J., and Nabel, E. G. (1998) Combination aeric delivery of the cell cycle inhibitor p27 with thymidine Kinase enhances prodrug cytotoxixity. J. Virol. 71, 9201-9207.
8. Estin, D., Li, M., Spray, D., and Wu, J. K. (1999) Connexins are espressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery 44, 361-369.
9. Gentry, B. G., Im, M., Boucher, P. D., Ruch, R. J., and Shewach, D. S. (2005) GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity. Gene Ther. 12, 1033-1041.
10. Gerolami, R., Uch, R., Brechot, C., Mannomi, P., and Bagnis, C. (2003) Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact. Cancer Gene Ther. 10, 649-660.
11. Gorlich, D. and Kutay, U. (1999) Transport between the cell nucleus and the cytoplasm. Annu. Rev. Cell Dev. Biol. 15, 607-660.
12. Goto, T., Nishi, T., Kobayashi, O., Tamura, T., Dev, S. B., et al. (2004) Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol. Ther. 10, 929-937.
13. Kamiya, H., Tsuchiya, H., Yamazaki, J., and Harashima, H. (2001) Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv. Drug Deliv. Rev. 52, 153-164.
14. Kokoris, M. S., Sabo, P., Adman, E. T., and Black, M. E. (1999) Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 6, 1415-1426.
15. Kokoris, M. S., Sabo, P., and Black, M. F. (2000) In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. 20, 959-963.
16. Marconi, P., Tamura, M., Moriuchui, S., Krisky, D. M., Niranjan, A., et al. (2000) Connexin 43-enghances suicide gene therapy using herpesviral vectors. Mol. Ther. 1, 71-81.
17. McNeish, I. A., Tenev, T., Bell, S., Marani, M., Vassaux, G., et al. (2001) Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells. Cancer Gene Ther. 8, 308-319.
18. Merilainen, O., Hakkarainen, T., Wahlfors, T., Pellinen, R., and Wahlfors, J. (2005) HYV-1 TAT protein Transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct. Int. J. Oncol. 27, 203-206.
19. Mohr, L., Yeung, A., Aloman, C., Wittrup, D., and Wands, J. R. (2004) Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology 127, S225-231.
20. Okuda, K. (2000) Hepatocellular carcinoma. J. Hepatol. 32, 225-237.
21. O'Malley, B. W., Cope, K. A., Chen, S. H., Li., D., Schwarta, M. R., et al. (1996) Combination gene therapy for oral cancer in a murine model. Cancer Res. 56, 1737-1741.
22. Patterson, A. V., Saunders, M. P., and Greco, O. (2003) Prodrugs, in genetic chemoradiotherapy. Curr. Pharm. Des. 9, 213-2154.
23. Qian, C., Bilbao, R., Bruna, O., and Prieto, J. (1995) Induction of sensitivity to ganciclovir in human hepatocelludar carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 22, 118-123.
24. Ren., W., Strube, R., Zhang, X., Chen, S. Y., and Huang, X. F. (2004) Potent tumor-specitic immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res. 64, 6645-6651.
25. Rexach, M. and Blobel, G. (1995) Protein import into nuclei: association and dissociation reactions involving transport substrate, transport factors, and nucleoporins. Cell 83, 683-692.
26. Ruiz, J., Mazzolini, G., Sangro, B., Qian, C., and Prieto, J. (2001) Gene therapy of hepatocellular carcinoma. Dig Dis. 19, 324-332.
27. Sachs, M. S., Selker, E. U., Lin, B., Roberts, C. J., Lou, Z., et al. (1997) Expression of herpes virus thymidine kinase in Neurospora crassa. Nucleic Acids Res. 25, 2389-2395.
28. Sa Cunha, A., Bonte, E., Dubois, S., Chretien, Y., Eraiser, T., et al. (2002) Inhibition of rat hepatocellular carcinoma tumor growth after multiple infusions of recombinant Ad. AFPtk followed by ganciclovir treatment. J. Hepatol. 37, 222-230.
29. Schwarze, S. R. and Dowdy, S. F. (2000) In vivo protein transduction: intracellular delivery of biologically active protiens, compounds and DNA. Trends Pharmacol. Sci. 21, 45-48.
30. Stetani, A. L., Barzon, L. Castagliuolo, I., Guido, M., Pacenti, M., et al. (2005) Systemic efficacy of combined suicied/cytokine gene therapy in a murine model of hepatocellular carcinoma. J. Hepatol. 42, 728-735.
31. Su. H., Lu. R., Ding, R., and Kan, Y. W. (2000) Adeno-associated viral-mediated gene transter to nepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in nonganciclovir (GCV)-treated than in GCV-treated animals. Mol. Ther. 1, 509-515.
32. Tanaka, M., Fraizer, G. C., De La Cerda, J., Cristiano, R. J., Liebert, M., et al. (2001) Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther. 8, 139-148.
33. Tasciotti, E., Zoppe, M., and Giacca, M. (2003) Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat. Cancer Gene Ther. 10, 64-74.
34. Vives, E., Brodin, P., and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010-16017.
35. Wandia, J. S. and Dowdy, S. F. (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57, 579-596.